On January 6, 2021 Purple Biotech Ltd. Presented the Corporate Presentation (Press release, Purple Biotech, JAN 6, 2021, View Source [SID1234573601]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On January 6, 2021 OBI Pharma, Inc., a Taiwan biopharma company (TPEx: 4174), reported that Tillman Pearce, MD., Chief Medical Officer, will present a company and clinical development overview at the 39th Annual J.P. Morgan Digital Healthcare Conference on Monday, January 11, 2021 at 11:00 a.m. EST/ 8:00 a.m. PST (Press release, OBI Pharma, JAN 6, 2021, View Source [SID1234573596]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The presentation slides will be available online at www.obipharma.com on January 12, 2021.

On January 6, 2021 Bausch Health Companies Inc. (NYSE/TSX: BHC) reported that Joseph C. Papa, chairman and chief executive officer, is scheduled to participate at the 39th Annual J.P. Morgan Healthcare Conference on Wednesday, Jan. 13, 2021 at 10:00 a.m. ET (Press release, Bausch Health, JAN 6, 2021, View Source [SID1234573595]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast and audio archive of the event will be available on the Investor Relations page of the Bausch Health Companies Inc. website at: View Source

On January 6, 2021 Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, reported that Douglas E. Onsi, President and Chief Executive Officer, will present a corporate overview at the H.C. Wainwright BioConnect 2021 Conference, being held virtually on January 11-14, 2021 (Press release, Leap Therapeutics, JAN 6, 2021, View Source [SID1234573594]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The presentation will be available on Monday, January 11 at 6:00 a.m. Eastern Time and may be accessed on the Investors page of the company’s website at View Source, where a replay of the event will also be available for a limited time.

On January 6, 2021 Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, reported that Marc N. Casper, chairman, president and chief executive officer, will present virtually at the 39th Annual J.P. Morgan Healthcare Conference on Monday, January 11, 2021, at 3:40 p.m. (EDT) (Press release, Thermo Fisher Scientific, JAN 6, 2021, View Source [SID1234573593]). Among other topics, Mr. Casper will provide the company’s current perspective on the impact of the COVID-19 pandemic and expectations for future financial performance.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

You can access the webcast of the presentation via the Investors section of our website, www.thermofisher.com.